

**HOGAN & HARTSON L.L.P.**

500 SOUTH GRAND AVENUE  
SUITE 1900  
LOS ANGELES, CA 90071

Tel.: (213) 337-6700

Fax: (213) 337-6701

RECEIVED  
CENTRAL FAX CENTER

MAY 15 2006

WASHINGTON, DC  
BRUSSELS  
BUDAPEST\*  
LONDON  
MOSCOW  
PARIS\*  
PRAGUE\*  
TOKYO  
WARSAW  
BALTIMORE, MD  
BOULDER, CO  
COLORADO SPRINGS, CO  
DENVER, CO  
IRVINE, CA  
MCLEAN, VA  
MIAMI, FL  
NEW YORK, NY (PARK AVE)  
NEW YORK, NY (THIRD AVE)  
ROCKVILLE, MD

\*Affiliated Office

**IMPORTANT NOTICE**  
**TELECOPY/FACSIMILE COVER LETTER**

TO: U.S. Patent and Trademark Office  
Examiner: Terra C. Gibbs  
Art Unit: 1635

DATE: May 15, 2006FROM: Barry M. Shuman

TIME: \_\_\_\_\_

TOTAL NO. OF PAGES, INCLUDING COVER: 13

The attached information is **CONFIDENTIAL** and is intended only for the use of the addressee(s) named above. If the reader of this message is not the intended recipient(s) or the employee or agent responsible for delivering the message to the intended recipient(s), please note that any dissemination, distribution or copying of this communication is strictly prohibited. Anyone who receives this communication in error should notify us immediately by telephone and return the original message to us at the above address via the U.S. Mail.

**MESSAGE:**

Patent Application No.: 10/663,875; Our Ref. 89188.0050

I hereby certify that the following documents:

- ☒ Response to Notice to Comply with Sequence Requirements /Amendment Transmittal Letter  
☒ Copy of Notice to Comply with Nucleotide Sequence Requirements

are being facsimiled to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450., for filing in the above-identified application.

May 15, 2006  
Date of Deposit

  
Diane Zynn

TELECOPY/FAX NUMBER: (571) 273-8300 ART UNIT 1635CLIENT NUMBER: 89188.0050ATTORNEY BILLING NUMBER: 6085CONFIRMATION NUMBER: (return fax to Diane Zynn)

FORM PTO-1083

89188.0050  
Patent Application No. 10/663,875

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED  
CENTRAL FAX CENTER

MAY 15 2006

In re application of:

Shi-Lung LIN, et al.

Serial No: 10/663,875

Filed: September 16, 2003

For: RNA-MEDIATED GENE MODULATION

Art Unit: 1635  
Examiner: Terra C. GibbsI hereby certify that this correspondence  
is being transmitted via facsimile to  
(571) 273-8300:  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450 on

May 15, 2006

Date of Deposit

Diane Zynn

Name

Signature *Diane Zynn* 05/15/06  
DateMail Stop Missing Parts  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Transmitted herewith is an amendment in the above-identified application, and:

- ☒ Copy of Notice to Comply with Nucleotide Sequence Requirements  
☒ No additional fee is required.

The fee has been calculated as shown below:

	(Col. 1) CLAIMS REMAINING AFTER AMENDMENT		(Col. 2) HIGHEST NUMBER PREVIOUSLY PAID FOR		(Col. 3) PRESENT EXTRA*	LG/SM \$ ENTITY FEE		ADD'L FEE DUE
TOTAL CLAIMS FEE	57	-	57	**	0	LG=\$60 SM=\$25	\$0	\$ 0
INDEPENDENT CLAIMS FEE	9	-	9	***	0	LG=\$100 SM=\$200	\$0	\$ 0
FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIMS						LARGE ENTITY FEE = \$380 SMALL ENTITY FEE = \$180		\$ 0
Independent Claims: 1, 7, 8, 25, 32, 39, 47, 48, 49						TOTAL		\$ 0

\* If the entry in Col. 1 is less than the entry in Col. 2, write "0" in Col. 3.

\*\* If the Highest Number Previously Paid For IN THIS SPACE is less than 20, write "20" in this space.

\*\*\* If the Highest Number Previously Paid For IN THIS SPACE is less than 3, write "3" in this space. The "Highest Number Previously Paid For" (Total or Independent) is the highest number found from the equivalent box on Col. 1 of a prior amendment or the number of claims originally filed.

- ☐ A check in the amount of \$\_\_\_ to cover the additional claims fee is enclosed. A copy of this sheet is enclosed.
- ☐ A check in the amount of \$\_\_\_ to cover the extension fee is enclosed. A copy of this sheet is enclosed.
- ☒ The Commissioner is hereby authorized to charge any deficiencies of fees associated with this communication or credit any overpayment to Deposit Account No. 50-1314. A copy of this sheet is enclosed.
- ☒ Any filing fees under 37 C.F.R. § 1.16 for the presentation of extra claims
- ☒ Any patent application processing fees under 37 C.F.R. § 1.17

Respectfully submitted,  
HOGAN & HARTSON LLPBy: *Barry M. Shuman*Barry M. Shuman  
Registration No. 50,220

Date: May 15, 2006

Biltmore Tower  
500 South Grand Avenue, Suite 1900  
Los Angeles, California 90071  
Telephone 213 337-6700  
Facsimile: 213 337-6701

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a))

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☐ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29820 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing".
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☒ 7. Other: See attached

**Applicant Must Provide:**

required if  
new  
sequences  
must be  
added to  
the listing

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing". (If the unidentified sequences are not provided on the CRF)
- ☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification, (If the unidentified sequences are not provided in the paper copy) ..
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d). (If a new paper and/or CRF are required)

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4218

For CRF Submission Help, call (703) 308-4212

PatentIn Software Program Support

Technical Assistance.....703-287-0200

To Purchase PatentIn Software.....703-306-2600

**PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY**